Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin

Gabriela Neculae1,2, Robert Adam1,2, Andreea Jercan1,3

  • 1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

ESC Heart Failure
|May 17, 2024
PubMed

Insights

This study developed a new scoring system to differentiate between transthyretin amyloidosis (ATTR) and light-chain amyloidosis (AL). The non-invasive checkpoints aid in faster, more accurate diagnosis of cardiac amyloidosis (CA).

Area of Science:

  • Cardiology
  • Biomarkers
  • Medical Diagnostics

Background:

  • Systemic amyloidosis (CA) is a complex disease with heterogeneous subtypes.
  • Accurate differential diagnosis between transthyretin amyloidosis (ATTR) and light-chain amyloidosis (AL) is crucial for patient management.
  • Current diagnostic methods can be extensive and time-consuming.

Purpose of the Study:

  • To establish a differential diagnosis algorithm for the two most frequent subtypes of cardiac amyloidosis (CA): ATTR and AL.
  • To identify non-invasive checkpoints to guide the decision-making process for CA diagnosis.

Main Methods:

  • Prospective inclusion of 81 consecutive patients with ATTR and AL amyloidosis.
  • Comprehensive evaluation including clinical data, biomarkers (NT-proBNP, hs-cTnI), GFR, and echocardiographic parameters (LV and RV strain, LA strain).
  • Development and validation of a scoring system based on calculated cut-off points and AUC values.

Main Results:

  • ATTR patients were younger and showed significantly different NT-proBNP, hs-cTnI, and GFR levels compared to AL patients.
  • ATTR group exhibited less pericardial effusion and better LV global longitudinal strain, RV strain, and LA strain reservoir function.
  • A scoring system with ≥4 points differentiated AL from ATTR with 80% sensitivity and 62% specificity in the derivation cohort, and 81% sensitivity and 77% specificity in the validation cohort.

Conclusions:

  • Cardiac amyloidosis (CA) diagnosis requires extensive testing.
  • A series of non-invasive checkpoints can effectively guide the decision-making process.
  • The developed scoring system offers a more accurate and rapid differential diagnosis for CA subtypes.
Abstract

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...